The DMD Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Huh-7 human hepatocellular carcinoma cell line, providing a loss-of-function model for the DMD gene. This polyclonal population contains a heterogeneous mix of cells with targeted disruption of the dystrophin-encoding gene, enabling robust and reproducible studies without the clonal bias of single-cell-derived lines.
The parental Huh-7 cell line originates from a well-differentiated hepatocellular carcinoma obtained from a 57-year-old Japanese male. These immortalized epithelial cells are widely utilized as a model system for liver function, hepatocyte metabolism, drug toxicity screening, and hepatocellular carcinoma research due to their stable growth characteristics and well-mapped signaling networks.
Dystrophin, encoded by DMD, is a 427 kDa cytoskeletal protein that forms the core of the dystrophin-glycoprotein complex (DGC). Through its N-terminal domain, dystrophin binds filamentous actin (F-actin), while its C-terminal region interacts with beta-dystroglycan, linking the actin cytoskeleton to the extracellular matrix via laminin. The DGC also includes sarcoglycans, syntrophins, dystrobrevin, and sarcospan, and serves as a scaffold for signaling molecules such as neuronal nitric oxide synthase (nNOS). Transcription of DMD is regulated by SP1, CREB1, and AP-1. In non-muscle cells, dystrophin modulates focal adhesion dynamics and calcium signaling, and its loss disrupts DGC integrity, impairing cell adhesion and mechanotransduction.
In the Huh-7 hepatocellular carcinoma context, DMD knockout provides a unique platform to dissect the roles of dystrophin in liver cell biology. Loss of dystrophin likely alters integrin-mediated adhesion, focal adhesion kinase signaling, and downstream cascades, potentially impacting cell migration, invasion, and proliferation. This model enables the exploration of how hepatic DGC dysfunction contributes to cancer cell behavior and whether dystrophin deficiency in the liver??as observed in some muscular dystrophy patients??has pathophysiological consequences. Additionally, it allows assessment of off-target effects of dystrophin-restoring therapies on hepatocytes.
Typical experimental applications include western blotting and immunofluorescence to confirm dystrophin ablation and assess DGC component expression, RT-qPCR for residual transcript quantification, cell adhesion and migration assays to evaluate functional deficits, and co-immunoprecipitation to analyze DGC complex assembly. These cells are suitable for high-throughput drug screening, genetic modifier screens, and RNA-seq transcriptomic profiling to identify pathways affected by dystrophin loss in liver cells. For additional details, cell line authentication data, or personalized support, please contact Ascent Research.
